α-Glucosidase inhibitive diarylheptanoids from Ottelia acuminata var. acuminata, a traditional vegetable of Bai Nationality in Yunnan
-
Published:2022-06-10
Issue:1
Volume:12
Page:
-
ISSN:2192-2195
-
Container-title:Natural Products and Bioprospecting
-
language:en
-
Short-container-title:Nat. Prod. Bioprospect.
Author:
Liu Hong-Xing, Ma Jun-Zeng, Ye Yan-Song, Zhao Jian-Jun, Wan Shi-Jie, Hu Xin-Yue, Xu GangORCID
Abstract
AbstractDiabetes is an urgent health issue characterized by ethnic and regional variations, and is inseparable from the different dietary habits. It is worthy to note that the incidence of diabetes in Bai nationality has been reported to be much lower than Han in China. As a daily vegetable of Bai, the phytochemical and antidiabetic study of Ottelia acuminata var. acuminata had not been carried out. In this study, 41 metabolites with diverse diarylheptanoid (six new ones, Otteacumienes A–F), flavone, sesquiterpenoid, coumarin, lignan, polyacetylene, and alkaloid skeletons were characterized from O. acuminata var. acuminata. Among them, the racemic nature of 3 was characterized by chiral resolution and calculated ECD methods. The biological study revealed diarylheptanoids showed significant α-glucosidase inhibitory activities with 5 as the most effective one (60-fold stronger than acarbose). Molecular docking studies indicated that these structures have different binding cavities with acarbose. This study demonstrated that O. acuminata var. acuminata might correlated with the low incidence diabetes of Bai and the diarylheptanoids may have potential therapeutic value for diabetes mellitus.
Graphical Abstract
Funder
the Second Tibetan Plateau Scientific Expedition and Research program State Key Laboratory of Phytochemistry and Plant Resources in West China
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Plant Science,Pharmacology,Toxicology,Biochemistry,Food Science,Analytical Chemistry
Reference51 articles.
1. International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th edn. (Brussels, Belgium, 2021). 2. Dahlen AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, Schioth HB. Trends in antidiabetic drug discovery: FDA approved drugs, New Drugs in clinical trials and global sales. Front Pharmacol. 2022;12:807548. 3. Hossain U, Das AK, Ghosh S, Sil PC. An overview on the role of bioactive alpha-glucosidase inhibitors in ameliorating diabetic complications. Food Chem Toxicol. 2020;145:111738. 4. Zhang LH, Chen QY, Li L, Kwong JSW, Jia PL, Zhao PJ, Wang W, Zhou X, Zhang MM, Sun X. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. Sci Rep-Uk. 2016;6:32649. 5. Li YZ, Teng D, Shi XG, Qin GJ, Qin YF, Quan HB, Shi BY, Sun H, Ba JM, Chen B, Du JL, He LJ, Lai XY, Li YB, Chi HY, Liao EY, Liu C, Liu LB, Tang XL, Tong NW, Wang GX, Zhang JA, Wang YM, Xue YM, Yan L, Yang J, Yang LH, Yao YL, Ye Z, Zhang Q, Zhang LH, Zhu J, Zhu M, Ning G, Mu YM, Zhao JJ, Teng WP, Shan ZY. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|